What is Alembic Pharmaceuticals Ltd. Quarterly Revenue?

Alembic Pharmaceuticals Ltd. Quarterly Revenue Alembic Pharma Jun-2026 Quarterly Revenue is Rs 1,882 Cr which is growth of 25.3% YoY.

What is Alembic Pharmaceuticals Ltd. Quarterly Net Profit?

Alembic Pharmaceuticals Ltd. Quarterly Net Profit Alembic Pharma Jun-2026 Quarterly Net Profit is Rs 197 Cr which is growth of 90.3% YoY.

What is Alembic Pharmaceuticals Ltd. Annual Revenue?

Alembic Pharmaceuticals Ltd. Annual Revenue Alembic Pharma Mar-2026 Annual Revenue is Rs 6,707 Cr which is growth of 10.3% YoY.

What is Alembic Pharmaceuticals Ltd. Annual Net Profit?

Alembic Pharmaceuticals Ltd. Annual Net Profit Alembic Pharma Mar-2026 Annual Net Profit is Rs 640 Cr which is growth of 27.3% YoY.

What is Alembic Pharmaceuticals Ltd. Total Shareholders Fund?

Alembic Pharmaceuticals Ltd. Total Shareholders Fund Alembic Pharma Mar-2026 Total Shareholders Fund is Rs 5,615 Cr which is growth of 8.1% YoY.

What is Alembic Pharmaceuticals Ltd. Total Assets?

Alembic Pharmaceuticals Ltd. Total Assets Alembic Pharma Mar-2026 Total Assets is Rs 8,151 Cr which is growth of 7.9% YoY.

What is Alembic Pharmaceuticals Ltd. Book Value Per Share?

Alembic Pharmaceuticals Ltd. Book Value Per Share Alembic Pharma Mar-2026 Book Value Per Share is 286 Rs which is growth of 8.1% YoY.

What is Alembic Pharmaceuticals Ltd. ROE?

Alembic Pharmaceuticals Ltd. ROE Alembic Pharma Mar-2026 ROE is 11% which is growth of 1.7% YoY.

What is Alembic Pharmaceuticals Ltd. Cash From Operating Activity?

Alembic Pharmaceuticals Ltd. Cash From Operating Activity Alembic Pharma Mar-2026 Cash From Operating Activity is Rs 809 Cr which is growth of 257.3% YoY.

What is Alembic Pharmaceuticals Ltd. Net Cash Flow?

Alembic Pharmaceuticals Ltd. Net Cash Flow Alembic Pharma Mar-2026 Net Cash Flow is Rs 8 Cr which is growth of 243.1% YoY.

Alembic Pharmaceuticals Ltd.

NSE: APLLTD | BSE: 533573

Mid-range Performer

Download real time

US FDA Inspections ANDA Approvals

-11.90(-1.49%)

123.8K

NSE+BSE Volume

NSE 12 Oct, 2026 3:31 PM (IST)

Portfolio

Alert

My Notes

Alembic Pharma quarterly and annual financials: results, revenue, profit, P&L, balance sheet, cash flow, financial ratios, revenue mix, peer comparison, and financial documents

View Charts

Forecaster Analyst Estimates for Alembic Pharma share price target, revenues, EPS, net income and more

Alembic Pharma quarterly results: revenue, profit, and P&L – 13 quarter history

Nested row level

Base Level

Reporting Type

Standalone

Cell Data

Actual

Table Settings

YoY & New to Old

Nested row level

Base Level

Export

POSITIVE
Quarterly Revenue Alembic Pharma Jun-2026 Quarterly Revenue is Rs 1,882 Cr which is growth of 25.3% YoY.
POSITIVE
Quarterly Net Profit Alembic Pharma Jun-2026 Quarterly Net Profit is Rs 197 Cr which is growth of 90.3% YoY.

Alembic Pharmaceuticals Ltd., Quarterly, standalone, All financials are in INR Cr and price data in INR
Indicator	Jun '26	Mar '26	Dec '25	Sep '25	Jun '25	Mar '25	Dec '24	Sep '24	Jun '24	Mar '24	Dec '23	Sep '23	Jun '23
TOTAL_SR_Q Total Rev. ⌄	1,882.1	1,744.6	1,653	1,807.7	1,502	1,583.9	1,421.6	1,596.4	1,478.7	1,481.8	1,591.7	1,487.8	1,344.1
SR_Q Operating Rev.	1,868.1	1,718.7	1,642.2	1,796.2	1,494.2	1,570.6	1,406.1	1,580.4	1,475.6	1,474.6	1,588.4	1,478.8	1,332.3
OI_Q Other Income	14	25.9	10.7	11.5	7.8	13.2	15.5	16.1	3.1	7.2	3.3	9	11.8
OEXPNS_Q Operating Exp.	1,522.3	1,444.7	1,370.6	1,492.9	1,280.4	1,400	1,226.3	1,320.9	1,184.1	1,186.4	1,251.3	1,271.4	1,166.5
OEXPNS_Q Operating Exp.	1,522.3	1,444.7	1,370.6	1,492.9	1,280.4	1,400	1,226.3	1,320.9	1,184.1	1,186.4	1,251.3	1,271.4	1,166.5
OP_Q Operating Profit	345.8	274.1	271.6	303.3	213.7	170.7	179.8	259.5	291.4	288.2	337.1	207.5	165.7
OPMPCT_Q Operating Profit Margin %	18.51%	15.95%	16.54%	16.89%	14.30%	10.87%	12.79%	16.42%	19.75%	19.54%	21.23%	14.03%	12.44%
DEP_Q Depr.	82.5	82.3	79.7	75.6	73.4	68.6	69.7	70.1	68.7	69.1	69.1	67.2	65.8
INT_Q Interest	21.4	19.4	21.7	22.8	22.6	23.7	21.8	18.3	12.7	10.1	14.7	15.4	14.3
PBT_Q Profit Before Tax	255.9	173.5	138.8	216.4	125.5	91.6	103.8	200	213.2	216.2	256.7	133.8	97.5
TAX_Q Tax	58.9	-69.6	24.3	37	22	16.2	18	34.2	37	14.3	23.5
NP_Q Net Profit	197	243.1	114.5	179.4	103.5	75.3	85.8	165.8	176.2	201.9	233.2	133.8	97.5
EPS_adj_Q EPS Adj. latest	10	12.4	5.8	9.1	5.3	3.8	4.4	8.4	9	10.3	11.9	6.8	5
NP_TTM Net profit TTM	733.9	640.4	472.7	444	430.5	503.1	629.7	777.1	745.1	666.5	595.2	481	493.6
EPS_TTM Basic EPS TTM	37.3	32.6	24.1	22.6	21.9	25.6	32	39.5	37.9	33.9	30.3	24.5	25.1
earnings_transcripts Earnings Transcripts
ai_summary AI Summary
results_pdf Results PDF
result_notes Result Notes	Notes	Notes	Notes	Notes	Notes		Notes	Notes	Notes	Notes	Notes	Notes	Notes

*All financials are in INR Cr and price data in INR

Add metric to table

Search...

Alembic Pharma competitor comparison and performance snapshot within industry

Alembic Pharma annual results: revenue, profit, P&L, and margins as of Mar 2026 – 11 year history

Nested row level

Base Level

Reporting Type

Standalone

Cell Data

Actual

Table Settings

YoY & New to Old

CAGR Columns

Select...

Nested row level

Base Level

Export

POSITIVE
Annual Revenue Alembic Pharma Mar-2026 Annual Revenue is Rs 6,707 Cr which is growth of 10.3% YoY.
POSITIVE
Annual Net Profit Alembic Pharma Mar-2026 Annual Net Profit is Rs 640 Cr which is growth of 27.3% YoY.

Alembic Pharmaceuticals Ltd., Annual, standalone, All financials are in INR Cr and price data in INR
Indicator	CAGR 3 Yrs	CAGR 5 Yrs	TTM	Mar '26	Mar '25	Mar '24	Mar '23	Mar '22	Mar '21	Mar '20	Mar '19	Mar '18	Mar '17	Mar '16
SR_A Total Rev. Ann. ⌄	9.2%	5.8%	7,087.4	6,707.3	6,080.5	5,905.4	5,152.5	5,086.6	5,061.2	4,267.3	3,666.7	2,951.3	2,958.9	2,997.3
TotalOperatingRevenues_A Operating Rev. Ann.	8.9%	5.7%	7,025.3	6,651.4	6,032.6	5,874.1	5,149	5,035.4	5,051.4	4,132.6	3,660.3	2,944.6	2,956.4	2,991.7
OI_A Other Income Ann.	151.8%	41.9%	62.1	55.9	47.9	31.3	3.5	51.1	9.7	134.8	6.4	6.7	2.4	5.5
OEXPNS_A Operating Exp. Ann.	7.6%	9.9%	5,830.5	5,588.7	5,131.2	4,875.5	4,484.7	4,126.6	3,479.2	2,929.7	2,781.6	2,312.1	2,323.2	2,009.7
OEXPNS_A Operating Exp. Ann.	7.6%	9.9%	5,830.5	5,588.7	5,131.2	4,875.5	4,484.7	4,126.6	3,479.2	2,929.7	2,781.6	2,312.1	2,323.2	2,009.7
OP_A Operating Profit Ann.	16.9%	-7.5%	1,194.8	1,062.7	901.4	998.5	664.4	908.8	1,572.2	1,202.9	878.7	632.5	633.3	982
OPMPCT_A OPM Ann. %	7.1%	-12.6%		15.84%	14.82%	16.91%	12.89%	17.87%	31.06%	28.19%	23.96%	21.43%	21.40%	32.76%
TotalExpenses_A Total Exp. Ann. ⌄	7.6%	10.4%		5,986.2	5,484.8	5,201.2	4,806.6	4,428.6	3,644.6	3,090.5	2,902.1	2,416.1	2,409.2	2,084
OtherExpenses_A Other Exp. Ann.	4%	9.2%	2,039	1,911.4	1,875.9	1,739.3	1,698.7	1,562.1	1,233	1,077.4	1,097.1	836.7	909.4	804
EmployeeBenefitExpenses_A Employee Exp. Ann.	13.8%	11.2%	1,633	1,612.9	1,466.6	1,335.9	1,094.8	1,062.3	948.3	806.4	684.5	582.7	527.5	404.3
CostOfPowerPurchased_A Cost Of Power Purchased Ann.	-	-
CostOfFuel_A Cost Of Fuel Ann.	-	-
EBIDT_A EBITDA Ann.	18.8%	-6.7%		1,118.6	949.3	1,029.8	667.9	959.9	1,582	1,337.7	885.1	639.2	635.7	987.5
EBIDTPCT_A EBITDA Ann. margin %	8.8%	-11.8%		16.68%	15.61%	17.44%	12.96%	18.87%	31.26%	31.35%	24.14%	21.66%	21.48%	32.95%
INT_A Interest Ann.	20.9%	46.5%	85.3	86.5	76.5	54.5	49	17	12.8	25.2	14.9	2.2	3.1	2.4
DEP_A Depr.	4.4%	15.3%	320.2	311	277.1	271.1	273	284.9	152.6	135.7	105.6	101.8	82.9	71.9
PBT_A PBT Ann.	23.7%	-14.3%	784.5	654.1	608.6	704.2	345.9	658	1,416.6	1,166.8	764.6	535.2	549.7	913.3
TAX_A Tax Ann.	-	-43.7%	50.6	13.7	105.5	37.8	-0.8	114.5	241.2	197.4	153.4	113.2	119.1	215.2
PAT_A PAT Before ExtraOrdinary Items Ann. ⌄	22.7%	-11.4%		640.4	503.1	666.5	346.7	543.6	1,175.4	969.4	611.2	422	430.6	698.1
IncomeMinorityInterest_A Minority Interest Income Ann.	-	-		-	-	-	-	-	-	-	-	-	-	-
NP_A Net Profit Ann.	22.7%	-11.4%	733.9	640.4	503.1	666.5	346.7	543.6	1,175.4	969.4	611.2	422	430.6	698.1
NETPCT_A NPM Ann. %	12.6%	-16.2%		9.62%	8.33%	11.34%	6.73%	10.79%	23.26%	23.45%	16.69%	14.33%	14.56%	23.33%
EPS_adj_A EPS Adj. latest Ann.	22.8%	-11.4%		32.6	25.6	33.9	17.6	27.7	59.8	49.3	31.1	21.5	21.9	35.5
result_notes Result Notes				Notes		Notes	Notes	Notes	Notes	Notes	Notes	Notes	Notes
Annual_Reports Annual Reports

*All financials are in INR Cr and price data in INR

Add metric to table

Search...

Total Rev. Ann.

1Y CHG

10.3%

2Y CAGR

6.6%

3Y CAGR

9.2%

5Y CAGR

5.8%

7Y CAGR

10Y CAGR

8.4%

Total Revenue Annual growth is higher than historical averages.

Net Profit Ann.

1Y CHG

27.3%

2Y CAGR

-2%

3Y CAGR

22.7%

5Y CAGR

-11.4%

7Y CAGR

0.7%

10Y CAGR

-0.9%

Net Profit Annual growth is higher than historical averages.

Operating Exp. Ann.

1Y CHG

8.9%

2Y CAGR

7.1%

3Y CAGR

7.6%

5Y CAGR

9.9%

7Y CAGR

10.5%

10Y CAGR

10.8%

Operating Expenses Annual Cr growth is stable compared to historical averages.

Alembic Pharma balance sheet as of Mar 2026: assets, liabilities, reserves, and borrowings – 11 year history

Nested row level

Base Level

Reporting Type

Standalone

Cell Data

Actual

Table Settings

YoY & New to Old

CAGR Columns

Select...

Nested row level

Base Level

Export

POSITIVE
Total Shareholders Fund Alembic Pharma Mar-2026 Total Shareholders Fund is Rs 5,615 Cr which is growth of 8.1% YoY.
POSITIVE
Total Assets Alembic Pharma Mar-2026 Total Assets is Rs 8,151 Cr which is growth of 7.9% YoY.

Alembic Pharmaceuticals Ltd., Balance Sheet, standalone, All financials are in INR Cr and price data in INR
Indicator	CAGR 3 Yrs	CAGR 5 Yrs	Mar '26	Mar '25	Mar '24	Mar '23	Mar '22	Mar '21	Mar '20	Mar '19	Mar '18	Mar '17	Mar '16
TotalShareHoldersFunds_A Total ShareHolders Funds Ann. ⌄	8.4%	1.3%	5,615.3	5,194.7	4,908.9	4,414.3	5,290.3	5,254.2	3,346	2,712.4	2,194.6	1,867.3	1,530.3
EQCAP_A Equity Share Capital Ann.	0%	0%	39.3	39.3	39.3	39.3	39.3	39.3	37.7	37.7	37.7	37.7	37.7
TotalShareCapital_A Total Share Capital Ann.	0%	0%	39.3	39.3	39.3	39.3	39.3	39.3	37.7	37.7	37.7	37.7	37.7
ReservesAndSurplus_A Reserves Plus Surplus Ann.	8.4%	1.3%	5,576	5,155.4	4,869.6	4,375	5,251	5,214.9	3,308.3	2,674.7	2,156.9	1,829.6	1,492.6
TotalReservesAndSurplus_A Total Reserves Plus Surplus Ann.	8.4%	1.3%	5,576	5,155.4	4,869.6	4,375	5,251	5,214.9	3,308.3	2,674.7	2,156.9	1,829.6	1,492.6
LiabilityMinorityInterest_A Minority Interest Liability Ann.	-	-	-	-	-	-	-	-	-	-	-	-	-
TotalNonCurrentLiabilities_A Total Non Current Liabilities Ann. ⌄	3%	-14.7%	179.9	161.9	162.4	164.8	204.3	398.5	1,079.3	595.9	606	113.6	91.3
DeferredTaxLiabilities_A Deferred Tax Liabilities Ann.	-	-					46.4	46.1	45.8	45.3	44.6	43.8	50
OtherLongTermLiabilities_A Other LongTerm Liabilities Ann.	-22.8%	-16.8%	27	37.6	52.9	58.6	62	67.7	73.3			12.6	13.1
CL_A Total Current Liabilities Ann. ⌄	14.9%	16%	2,356.1	2,199.6	1,327.2	1,551.3	1,579.5	1,123.5	1,453.5	1,240.7	877.3	526.9	567.5
TradePayables_A Trade Payables Ann.	3.5%	5%	660.7	724.6	620	595.9	570.2	516.9	393.2	529.9	602	465.8	500.2
OtherCurrentLiabilities_A Other Current Liabilities Ann.	20.3%	-4.7%	435.5	247.5	222.3	250.4	315.6	554.9	222.1	318.5	140.3	48.8	51.3
ShortTermProvisions_A ST Provisions Ann.	16.4%	16.4%	110.4	85.3	64.9	70	63.6	51.6	38.2	32.4	13.5	12.3	16
TL_A Total Capital Plus Liabilities Ann.	10%	3.8%	8,151.3	7,556.3	6,398.5	6,130.4	7,074	6,776.2	5,878.8	4,549	3,677.9	2,507.8	2,189.1
FixedAssets_A Fixed Assets Ann. ⌄	5.6%	0.7%	3,511.8	3,350.7	3,060	2,978.7	4,075.3	3,388.8	2,846.4	2,192.3	1,658.9	1,146.8	789.6
TangibleAssets_A Tangible Assets Ann.	6%	14.3%	2,828.4	2,513.5	2,535.7	2,377.5	1,714.7	1,452.8	1,268.1	1,077.1	918.3	799	697.3
IntangibleAssets_A Intangible Assets Ann.	-	-					56.4
CapitalWorkInProgress_A Capital Work In Progress Ann.	1.8%	-19.9%	633.7	837.2	524.4	601.3	2,205.8	1,927.6	1,570	1,106.9	740.6	347.8	92.3
TotalNonCurrentAssets_A Total Non Current Assets Ann. ⌄	7.1%	-1.3%	4,120.2	3,790.1	3,410	3,350.2	4,329.6	4,402.2	3,727.4	2,713	2,002.2	1,286.3	875.8
NonCurrentInvestments_A Non Current Investments Ann.	5.8%	-22.6%	271.4	259.6	226.7	229.3	219.4	978.3	833.3	506.4	298.9	103	37.5
DeferredTaxAssets_A Deferred Tax Assets Ann.	32%	-	179.7	77.4	78.8	78.2
LongTermLoansAndAdvances_A LT Loans Plus Advances Ann.	139.7%	-	141.9	71.2	11.2	10.3						36.5	48.8
OtherNonCurrentAssets_A Other Non Current Assets Ann.	-34.1%	-15.2%	15.4	31.2	33.3	53.8	34.9	35.2	47.7	14.3	44.4
CA_A Total Current Assets Ann. ⌄	13.2%	11.2%	4,031	3,766.2	2,988.6	2,780.2	2,744.5	2,374	2,151.4	1,836	1,675.7	1,221.5	1,313.3
CurrentInvestments_A Current Investments Ann.	-	-						187
TradeReceivables_A Trade Receivables Ann.	10.1%	31.5%	1,603.8	1,480.7	1,340.1	1,201.2	988.3	407.9	784.1	539.8	621.7	466.1	371.5
CashAndCashEquivalents_A Cash Plus Cash Equivalents Ann.	0.2%	-14.1%	28.7	20.9	26.5	28.5	21.9	61.2	37.1	150.8	15.6	0.7	284.8
ShortTermLoansAndAdvances_A ST Loans Plus Advances Ann.	-	-	12.2	12.9								20.2	123.3
OtherCurrentAssets_A Other Current Assets Ann.	7.1%	-3.4%	338.2	275.5	268.9	275.4	337.4	401.1	256.9	254.1	368.5	159.9
TA_A Total Assets Ann.	10%	3.8%	8,151.3	7,556.3	6,398.5	6,130.4	7,074	6,776.2	5,878.8	4,549	3,677.9	2,507.8	2,189.1
ContingentLiabilities_A Contingent Liabilities plus Commitments Ann.	22.3%	12.8%	596.5	240.5	193.6	326.2	228.2	327.1	455.6	409.1	317.9	394.8
BonusEquityShareCapital_A Bonus Equity Share Capital Ann.	-	-
NonCurrentInvestmentsUnquotedBookValue_A Non Current Investments Unquoted Book Value Ann.	5.8%	-22.6%	271.4	259.6	226.7	229.3	219.4	978.3	833.3	506.4	298.9	103	37.5
CurrentInvestmentsUnquotedBookValue_A Current Investments Unquoted Book Value Ann.	-	-

*All financials are in INR Cr and price data in INR

Add metric to table

Search...

Total Assets Ann.

1Y CHG

7.9%

2Y CAGR

12.9%

3Y CAGR

10%

5Y CAGR

3.8%

7Y CAGR

8.7%

10Y CAGR

14.1%

Total Assets Annual growth is stable compared to historical averages.

Total Current Liabilities Ann.

1Y CHG

7.1%

2Y CAGR

33.2%

3Y CAGR

14.9%

5Y CAGR

16%

7Y CAGR

9.6%

10Y CAGR

15.3%

Total Current Liabilities Annual Cr growth is lower than historical averages.

Total ShareHolders Funds Ann.

1Y CHG

8.1%

2Y CAGR

3Y CAGR

8.4%

5Y CAGR

1.3%

7Y CAGR

11%

10Y CAGR

13.9%

Total ShareHolders Funds Annual growth is stable compared to historical averages.

Alembic Pharma ROE, ROCE, book value, and debt-to-equity ratio as of Mar 2026 – 11 year history

Nested row level

Base Level

Reporting Type

Standalone

Cell Data

Actual

Table Settings

YoY & New to Old

CAGR Columns

Select...

Nested row level

Base Level

Export

POSITIVE
Book Value Per Share Alembic Pharma Mar-2026 Book Value Per Share is 286 Rs which is growth of 8.1% YoY.
POSITIVE
ROE Alembic Pharma Mar-2026 ROE is 11% which is growth of 1.7% YoY.

Alembic Pharmaceuticals Ltd., Ratios, standalone, All financials are in INR Cr and price data in INR
Indicator	CAGR 3 Yrs	CAGR 5 Yrs	Mar '26	Mar '25	Mar '24	Mar '23	Mar '22	Mar '21	Mar '20	Mar '19	Mar '18	Mar '17	Mar '16
BVSH_A BVSH Ann.	8.4%	1.3%	285.7	264.3	249.8	224.6	269.2	267.3	177.5	143.9	116.4	99.1	81.2
ROA_A RoA Ann. %	11.6%	-14.7%	7.85%	6.65%	10.41%	5.65%	7.68%	17.34%	16.48%	13.43%	11.47%	17.17%	31.89%
ROE_A ROE Ann. %	13.2%	-12.6%	11.40%	9.68%	13.57%	7.85%	10.27%	22.37%	28.97%	22.53%	19.22%	23.06%	45.62%
ROCE_A ROCE Ann. %	17.3%	-11.2%	13.93%	12.54%	14.96%	8.62%	12.28%	25.28%	27.16%	23.56%	19.19%	27.90%	56.46%
ProfitabilityHeader Profitability Ratio ⌄
PBDITMargin_A EBITDA Ann. Margin %	9%	-11.7%	16.81%	15.73%	17.53%	12.97%	19.06%	31.31%	32.36%	24.18%	21.70%	21.50%	33.00%
PBITMargin_A EBIT Ann. Margin %	16.5%	-15.6%	12.14%	11.14%	12.91%	7.67%	13.40%	28.29%	29.08%	21.29%	18.25%	18.69%	30.60%
PBTMargin_A PBT Ann. Margin %	13.6%	-18.9%	9.83%	10.08%	11.98%	6.71%	13.06%	28.04%	28.23%	20.88%	18.17%	18.59%	30.52%
NETPCT_A NPM Ann. %	12.6%	-16.2%	9.62%	8.33%	11.34%	6.73%	10.79%	23.26%	23.45%	16.69%	14.33%	14.56%	23.33%
ASETTO_A Asset Turnover Ann. %	4%	2.4%	0.9	0.9	0.9	0.8	0.7	0.8	0.8	0.9	1	1.3	1.6
LiquidityHeader Liquidity Ratio ⌄
CRATIO_A Current Ratio Ann.	-1.9%	-4.1%	1.7	1.7	2.3	1.8	1.7	2.1	1.5	1.5	1.9	2.3	2.3
QuickRatio_A Quick Ratio Ann.	-7.2%	-2.3%	0.8	0.8	1.2	1	0.9	0.9	0.7	0.8	1.2	1.2	1.4
DividendPayoutNP_A Dividend Payout to NP Ann.	-9.1%	-	0.3	0.4	0.2	0.4	0.4		0.3	0.1	0.2	0.2	0.1
EarningRetention_A Earning Retention Ann. %	15.2%	-	66.24%	57.03%	76.41%	43.32%	49.38%		69.86%	87.67%	78.50%	78.93%
CashEarningRetention_A Cash Earning Retention Ann. %	4.2%	-	77.28%	72.29%	83.23%	68.29%	66.79%		73.56%	89.48%	82.68%	82.33%
CashEarningRetention_A Cash Earning Retention Ann. %	4.2%	-	77.28%	72.29%	83.23%	68.29%	66.79%		73.56%	89.48%	82.68%	82.33%
ValuationHeader Valuation Ratio ⌄
EnterpriseValue_A EnterpriseValue Ann.	10.9%	-5.9%	14,129.4	19,385.8	19,701.6	10,354.5	15,179.3	19,108.7	11,709.2	10,709.4	10,969.6	11,755.1	11,037.5
EVPerNetSales_A EV Per Net Sales Ann.	1.6%	-11.2%	2.1	3.2	3.4	2	3	3.8	2.8	2.9	3.7	4	3.7
PBV_A Price To Book Value Adjusted	-7.7%	-1.3%	2.76	3.08	3.16	3.51	2.93	2.95	4.44	5.48	6.78	7.96	9.72
EVPerEBITDA_A EV Per EBITDA Ann.	-6.7%	0.8%	12.6	20.4	19.1	15.5	15.8	12.1	8.8	12.1	17.2	18.5	11.2
MarketCapPerSales_A Market Cap Per Sales Ann.	1.7%	-12%	2	3	3.3	1.9	2.9	3.8	2.4	2.7	3.5	4	3.8
RetentionRatios_A Retention Ratio Ann. %	15.2%	-	66.23%	57.02%	76.40%	43.31%	49.37%		69.85%	87.66%	78.49%	78.92%
EYield_A Earnings Yield Ann.	-	0%	0.1	0	0	0	0	0.1	0.1	0.1	0	0	0.1
DEBT_CE_A Total Debt to Total Equity Ann.	26%	-	0.2	0.2	0.1	0.1	0.1	0	0.5	0.3	0.3

*All financials are in INR Cr and price data in INR

Add metric to table

Search...

ROE Ann. %

1Y CHG

17.8%

2Y CAGR

-8.3%

3Y CAGR

13.2%

5Y CAGR

-12.6%

7Y CAGR

-9.3%

10Y CAGR

-12.9%

ROE Annual % is growing faster than historical averages.

RoA Ann. %

1Y CHG

18%

2Y CAGR

-13.2%

3Y CAGR

11.6%

5Y CAGR

-14.7%

7Y CAGR

-7.4%

10Y CAGR

-13.1%

RoA Annual % is growing faster than historical averages.

Current Ratio Ann.

2Y CAGR

-14%

3Y CAGR

-1.9%

5Y CAGR

-4.1%

7Y CAGR

1.8%

10Y CAGR

-3%

Current Ratio Annual is falling faster than historical averages.

Alembic Pharma cash flow: net, operating, investing, and financing flows as of Mar 2026 – 11 year history

Nested row level

Base Level

Reporting Type

Standalone

Cell Data

Actual

Table Settings

YoY & New to Old

CAGR Columns

Select...

Nested row level

Base Level

Export

POSITIVE
Cash From Operating Activity Alembic Pharma Mar-2026 Cash From Operating Activity is Rs 809 Cr which is growth of 257.3% YoY.
POSITIVE
Net Cash Flow Alembic Pharma Mar-2026 Net Cash Flow is Rs 8 Cr which is growth of 243.1% YoY.

Alembic Pharmaceuticals Ltd., Cash Flow, standalone, All financials are in INR Cr and price data in INR
Indicator	CAGR 3 Yrs	CAGR 5 Yrs	Mar '26	Mar '25	Mar '24	Mar '23	Mar '22	Mar '21	Mar '20	Mar '19	Mar '18	Mar '17	Mar '16
CFO_A Cash from Operating Act. Ann. ⌄	3.5%	-11.4%	809.5	226.6	772.8	730.3	545.3	1,485.3	539.8	808.8	304.6	320.6	847.5
PBT_A PBT Ann.	23.7%	-14.3%	654.1	608.6	704.2	345.9	658	1,416.6	1,166.8	764.6	535.2	549.7	913.3
INT_A Interest Ann.	20.9%	46.5%	86.5	76.5	54.5	49	17	12.8	25.2	14.9	2.2	3.1	2.4
TAX_A Tax Ann.	-	-43.7%	13.7	105.5	37.8	-0.8	114.5	241.2	197.4	153.4	113.2	119.1	215.2
CFI_A Cash from Investing Act. Ann.	-	-	-483.4	-636.1	-329	-461	-368.7	-925.6	-822.3	-753.6	-793.6	-504.5	-293.1
CFA_A Cash from Financing Act. Ann.	-	-	-317.6	403.6	-445.3	-261.2	-216.6	-533.6	166.1	79.7	497.8	-96	-274.1
NCF_A Net Cash Flow Ann. ⌄	1.2%	-20.3%	8.4	-5.9	-1.5	8.1	-40.1	26.2	-116.4	134.9	8.8	-279.9	280.4
CashAndCashEquivalentBeginOfYear_A Cash Plus Cash Eqv. Begin Of Year Ann.	1.4%	-12.8%	14.2	20.1	21.7	13.6	53.7	28.2	144.2	9.5	0.7	280.6	4.4
CashAndCashEquivalentEndOfYear_A Cash Plus Cash Eqv. End Of Year Ann.	1.5%	-15.7%	22.7	14.2	20.1	21.7	13.6	53.4	28.2	144.3	9.5	0.7	284.8

*All financials are in INR Cr and price data in INR

Add metric to table

Search...

Cash from Operating Act. Ann.

1Y CHG

257.2%

2Y CAGR

2.3%

3Y CAGR

3.5%

5Y CAGR

-11.4%

7Y CAGR

10Y CAGR

-0.5%

Cash from Operating Activity Annual growth is higher than historical averages.

Alembic Pharma investor presentations, annual reports, credit ratings, and earnings calls with AI summary, video, and audio access

Forecaster
Quarterly
Competitors/Peers
Annual
Balance Sheet
Ratios
Cash Flow
Documents

Alembic Pharma quarterly and annual financials: results, revenue, profit, P&L, balance sheet, cash flow, financial ratios, revenue mix, peer comparison, and financial documents

Alembic Pharma - Forecaster

Forecaster Analyst Estimates for Alembic Pharma share price target, revenues, EPS, net income and more